Antiepileptic drugs for the treatment of impulsivity

Current Psychiatry Reviews

Volumn 4, Issue 3, 2008, Pages 114-136

  Berlin, Heather A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anticonvulsant; Antiepileptic drugs; Borderline personality disorder; Impulse controls disorders; Impulsivity; Pathological gambling

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CLONAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; ETIRACETAM; GABAPENTIN; GLUTAMIC ACID; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; NORADRENALIN; OPIATE ANTAGONIST; OXCARBAZEPINE; PHENYTOIN; PLACEBO; QUETIAPINE; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID;

ANTICONVULSANT ACTIVITY; AUTOMUTILATION; BINGE EATING DISORDER; BORDERLINE STATE; CLINICAL TRIAL; CLUSTER B PERSONALITY DISORDER; COMORBIDITY; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENT RELATED POTENTIAL; EVIDENCE BASED PRACTICE; HUMAN; IMPULSE CONTROL DISORDER; IMPULSIVENESS; LOW DRUG DOSE; MELANCHOLIA; MONOTHERAPY; ORBITAL CORTEX; OUTCOME ASSESSMENT; PATHOLOGICAL GAMBLING; PATIENT COMPLIANCE; PERSONALITY DISORDER; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 53649104004     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340008785829922     Document Type: Review

References (191)

1. Evenden JL. Varieties of impulsivity. Psychopharmacology (Berl) 1999; 146: 348-361.
2. Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC. Psychiatric aspects of impulsivity. Am J Psychiatry 2001; 158: 1783-1793.
3. Virkkunen M. Reactive hypoglycemic tendency among habitually violent offenders. Nutr Rev 1986; 44 Suppl: 94-103.
4. Pattison EM, Kahan J. The deliberate self-harm syndrome. Am J Psychiatry 1983; 140: 867-872.
5. Cold JW. Axis II disorders and motivation for serious criminal behavior. In: Skodal AE ed, Psychopathology and Violent Crime. Washington, DC: American Psychiatric Press; 1998.
6. Hollander E, Berlin HA. Neuropsychiatric aspects of aggression and impulse control disorders. In: Yudofsky SC, Hales RE eds, American Psychiatric Press Textbook of Neuropsychiatry and Clinical Neurosciences. Washington, DC: American Psychiatric Press; in press.
7. Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003; 28: 1186-1197.
8. Critchfield KL, Levy KN, Clarkin JF. The relationship between impulsivity, aggression, and impulsive-aggression in borderline personality disorder: an empirical analysis of self-report measures. J Personal Disord 2004; 18: 555-570.
9. Hollander E, Rosen J. Impulsivity. J Psychopharmacol 2000; 14: S39-44.
10. Fineberg NA, Hollander E, Potenza MN, et al. Probing compulsive and impulsive behaviours, from animal models to endophenotypes: A narrative review. Am J Psychiatry In preparation
11. Davidson RJ. Anxiety and affective style: role of prefrontal cortex and amygdala. Biol Psychiatry 2002; 51: 68-80.
12. Davis M, Whalen PJ. The amygdala: vigilance and emotion. Mol Psychiatry 2001; 6: 13-34.
13. Rolls ET, Hornak J, Wade D, McGrath J. Emotion-related learning in patients with social and emotional changes associated with frontal lobe damage. J Neurol Neurosurg Psychiatry 1994; 57: 1518-1524.
14. Hornak J, Bramham J, Rolls ET, et al. Changes in emotion after circumscribed surgical lesions of the orbitofrontal and cingulate cortices. Brain 2003; 126: 1691-1712.
15. Hornak J, O'Doherty J, Bramham J, et al. Reward-related reversal learning after surgical excisions in orbito-frontal or dorsolateral prefrontal cortex in humans. J Cogn Neurosci 2004; 16: 463-478.
16. Hornak J, Rolls ET, Wade D. Face and voice expression identification in patients with emotional and behavioural changes following ventral frontal lobe damage. Neuropsychologia 1996; 34: 247-261.
17. Drevets WC. Functional neuroimaging studies of depression: the anatomy of melancholia. Annu Rev Med 1998; 49: 341-361.
18. van Reekum R. Acquired and developmental brain dysfunction in borderline personality disorder. Can J Psychiatry 1993; 38 Suppl 1: S4-10.
19. Berlin HA, Rolls ET, Iversen SD. Borderline personality disorder, impulsivity, and the orbitofrontal cortex. Am J Psychiatry 2005; 162: 2360-2373.
20. Tebartz van Elst L, Hesslinger B, Thiel T, et al. Frontolimbic brain abnormalities in patients with borderline personality disorder: a volumetric magnetic resonance imaging study. Biol Psychiatry 2003; 54: 163-171.
21. Herpertz SC, Dietrich TM, Wenning B, et al. Evidence of abnormal amygdala functioning in borderline personality disorder: a functional MRI study. Biol Psychiatry 2001; 50: 292-298.
22. Baxter MG, Parker A, Lindner CC, Izquierdo AD, Murray EA. Control of response selection by reinforcer value requires interaction of amygdala and orbital prefrontal cortex. J Neurosci 2000; 20: 4311-4319.
23. Rolls ET. The Brain and Emotion. Oxford: Oxford University Press; 1999.
24. Asconape JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol 2002; 22: 27-39.
25. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002; 63: 442-446.
26. Soloff PH. Psychopharmacology of borderline personality disorder. Psychiatr Clin North Am 2000; 23: 169-192, ix.
27. Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am 1997; 20: 427-451.
28. Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001; 62: 199-203
29. Hollander E, Swann AC, Coccaro EF, Jiang P, Smith TB. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 2005; 162: 621-624.
30. Tariot PN, Schneider L, Mintzer JE, et al. Safety and tolerability of divalproex sodium in the treatment of signs and symtpoms of mania in elderly patients with dimentia: Results of a double-blind, placebo-controlled trial. Curr Ther Res 2001; 62: 51-57.
31. Wulsin L, Bachop M, Hoffman D. Group therapy in manic-depressive illness. Am J Psychother 1988; 42: 263-271.
32. Simeon D, Baker B, Chaplin W, Braun A, Hollander E. An open-label trial of divalproex extended-release in the treatment of borderline personality disorder. CNS Spectr 2007; 12: 439-443.
33. Townsend MH, Cambre KM, Barbee JG. Treatment of borderline personality disorder with mood instability with divalproex sodium: series of ten cases. J Clin Psychopharmacol 2001; 21: 249-251
34. Wilcox JA. Divalproex sodium as a treatment for borderline personality disorder. Ann Clin Psychiatry 1995; 7: 33-37.
35. Zanarini MC. Update on pharmacotherapy of borderline personality disorder. Curr Psychiatry Rep 2004; 6: 66-70.
36. Donovan SJ, Susser ES, Nunes EV, et al. Divalproex treatment of disruptive adolescents: a report of 10 cases. J Clin Psychiatry 1997; 58: 12-15.
37. Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 2000; 157: 818-820.
38. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 1991; 52: 361-364.
39. Szymanski HV, Olympia J. Divalproex in posttraumatic stress disorder. Am J Psychiatry 1991; 148: 1086-1087.
40. Petty F, Davis LL, Nugent AL, et al. Valproate therapy for chronic, combat-induced posttraumatic stress disorder. J Clin Psychopharmacol 2002; 22: 100-101.
41. Giakas WJ, Seibyl JP, Mazure CM. Valproate in the treatment of temper outbursts. J Clin Psychiatry 1990; 51: 525.
42. Wroblewski BA, Joseph AB, Kupfer J, Kalliel K. Effectiveness of valproic acid on destructive and aggressive behaviours in patients with acquired brain injury. Brain Inj 1997; 11: 37-47.
43. Horne M, Lindley SE. Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes. J Clin Psychiatry 1995; 56: 430-431.
44. Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001; 9: 58-66.
45. Buchalter EN, Lantz MS. Treatment of impulsivity and aggression in a patient with vascular dementia. Geriatrics 2001; 56: 53-54.
46. Porsteinsson AP, Tariot PN, Jakimovich LJ, et al. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. Am J Geriatr Psychiatry 2003; 11: 434-440.
47. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 2001; 62: 530-534.
48. Hellings JA, Weckbaugh M, Nickel EJ, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005; 15: 682-692.
49. Barzman DH, DelBello MP, Adler CM, Stanford KE, Strakowski SM. The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s). J Child Adolesc Psychopharmacol 2006; 16: 665-670.
50. Barzman DH, McConville BJ, Masterson B, et al. Impulsive aggression with irritability and responsive to divalproex: a pediatric bipolar spectrum disorder phenotype? J Affect Disord 2005; 88: 279-285.
51. Saxena K, Howe M, Simeonova D, Steiner H, Chang K. Divalproex sodium reduces overall aggression in youth at high risk for bipolar disorder. J Child Adolesc Psychopharmacol 2006; 16: 252-259.
52. Miyazaki M, Ito H, Saijo T, et al. Favorable response of ADHD with giant SEP to extended-release valproate. Brain Dev 2006; 28: 470-472.
53. Steiner H, Saxena KS, Carrion V, et al. Divalproex sodium for the treatment of PTSD and conduct disordered youth: a pilot randomized controlled clinical trial. Child Psychiatry Hum Dev 2007; 38: 183-193.
54. Weinberger DR. Distress and self-restraint as measures of adjustment across the life span: Confirmatory factor analysis in clinical and nonclinical samples. Psychol Assess 1997; 9: 132-135.
55. Mattes JA. Psychopharmacology of temper outbursts. A review. J Nerv Ment Dis 1986; 174: 464-470.
56. Azouvi P, Jokic C, Attal N, et al. Carbamazepine in agitation and aggressive behaviour following severe closed-head injury: results of an open trial. Brain Inj 1999; 13: 797-804.
57. Chatham-Showalter PE. Carbamazepine for combativeness in acute traumatic brain injury. J Neuropsychiatry Clin Neurosci 1996; 8: 96-99.
58. Kafantaris V, Campbell M, Padron-Gayol MV, et al. Carbamazepine in hospitalized aggressive conduct disorder children: an open pilot study. Psychopharmacol Bull 1992; 28: 193-199.
59. Cueva JE, Overall JE, Small AM, et al. Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1996; 35: 480-490.
60. De Vogelaer J. Carbamazepine in the treatment of psychotic and behavioral disorders. A pilot study. Acta Psychiatr Belg 1981; 81: 532-541.
61. Thibaut F, Colonna L. Carbamazepine and aggressive behavior: A review. Encephale 1993; 19: 651-656.
62. Mattes JA. Comparative effectiveness of carbamazepine and propranolol for rage outbursts. J Neuropsychiatry Clin Neurosci 1990; 2: 159-164.
63. Freymann N, Michael R, Dodel R, Jessen F. Successful treatment of sexual disinhibition in dementia with carbamazepine - a case report. Pharmacopsychiatry 2005; 38: 144-145.
64. Munoz P, Gonzalez Torres MA. Organic personality disorder: response to carbamazepine. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1997; 25: 197-200.
65. Morikawa M, Iida J, Tokuyama A, et al. Successful treatment using low-dose carbamazepine for a patient of personality change after mild diffuse brain injury. Nihon Shinkei Seishin Yakurigaku Zasshi 2000; 20: 149-153.
66. Lewin J, Sumners D. Successful treatment of episodic dyscontrol with carbamazepine. Br J Psychiatry 1992; 161: 261-262.
67. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159: 1-50.
68. Mattes JA. Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2005; 25: 575-579.
69. Cordas TA, Tavares H, Calderoni DM, Stump GV, Ribeiro RB. Oxcarbazepine for self-mutilating bulimic patients. Int J Neuropsychopharmacol 2006; 9: 769-771.
70. Teter CJ, Early JJ, Gibbs CM. Treatment of affective disorder and obesity with topiramate. Ann Pharmacother 2000; 34: 1262-1265.
71. Smathers SA, Wilson JG, Nigro MA. Topiramate effectiveness in Prader-Willi syndrome. Pediatr Neurol 2003; 28: 130-133.
72. Janowsky DS, Kraus JE, Barnhill J, Elamir B, Davis JM. Effects of topiramate on aggressive, self-injurious, and disruptive/destructive behaviors in the intellectually disabled: an open-label retrospective study. J Clin Psychopharmacol 2003; 23: 500-504.
73. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000; 61: 368-372.
74. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 160: 255-261.
75. Carter WP, Hudson JI, Lalonde JK, et al. Pharmacologic treatment of binge eating disorder. Int J Eat Disord 2003; 34 Suppl: S74-88.
76. Pederson KJ, Roerig JL, Mitchell JE. Towards the pharmacotherapy of eating disorders. Expert Opin Pharmacother 2003; 4: 1659-1678.
77. Appolinario JC, McElroy SL. Pharmacological approaches in the treatment of binge eating disorder. Curr Drug Targets 2004; 5: 301-307.
78. Appolinario JC, Fontenelle LF, Papelbaum M, Bueno JR, Coutinho W. Topiramate use in obese patients with binge eating disorder: an open study. Can J Psychiatry 2002; 47: 271-273.
79. McElroy SL, Shapira NA, Arnold LM, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry 2004; 65: 1463-1469.
80. Zilberstein B, Pajecki D, Garcia de Brito AC, et al. Topiramate after adjustable gastric banding in patients with binge eating and difficulty losing weight. Obes Surg 2004; 14: 802-805.
81. Dolberg OT, Barkai G, Gross Y, Schreiber S. Differential effects of topiramate in patients with traumatic brain injury and obesity-a case series. Psychopharmacology (Berl) 2005; 179: 838-845.
82. Guerdjikova AI, Kotwal R, McElroy SL. Response of recurrent binge eating and weight gain to topiramate in patients with binge eating disorder after bariatric surgery. Obes Surg 2005; 15: 273-277.
83. De Bernardi C, Ferraris S, D'Innella P, Do F, Torre E. Topiramate for binge eating disorder. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 339-341.
84. Nickel C, Lahmann C, Tritt K, et al. Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study. J Affect Disord 2005; 87: 243-252.
85. Chengappa KN, Rathore D, Levine J, et al. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord 1999; 1: 42-53.
86. Cassano P, Lattanzi L, Pini S, et al. Topiramate for self-mutilation in a patient with borderline personality disorder. Bipolar Disord 2001; 3: 161.
87. Dolengevich Segal H, Rodriguez Salgado B, Conejo Garcia A, San Sebastian Cabases J. [Efficacy of topiramate in children and adolescent with problems in impulse control: preliminary results]. Actas Esp Psiquiatr 2006; 34: 280-282.
88. Rugino TA, Samsock TC. Levetiracetam in autistic children: an open-label study. J Dev Behav Pediatr 2002; 23: 225-230.
89. Grunze H, Langosch J, Born C, Schaub G, Walden J. Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. J Clin Psychiatry 2003; 64: 781-784.
90. Kaufman KR. Monotherapy treatment of bipolar disorder with levetiracetam. Epilepsy Behav 2004; 5: 1017-1020.
91. Simon NM, Worthington JJ, Doyle AC, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 2004; 65: 1219-1222.
92. Wasserman S, Iyengar R, Chaplin WF, et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol 2006; 21: 363-367.
93. Neuwirth M, Saracz J, Hegyi M, et al. [Experience with levetiracetam in childhood epilepsy]. Ideggyogy Sz 2006; 59: 179-182.
94. Opp J, Tuxhorn I, May T, et al. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Seizure 2005; 14: 476-484.
95. Weber S, Beran RG. A pilot study of compassionate use of Levetiracetam in patients with generalised epilepsy. J Clin Neurosci 2004; 11: 728-731.
96. Dinkelacker V, Dietl T, Widman G, Lengler U, Elger CE. Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy Behav 2003; 4: 537-547.
97. Cherek DR, Tcheremissine OV, Lane SD, Pietras CJ. Acute effects of gabapentin on laboratory measures of aggressive and escape responses of adult parolees with and without a history of conduct disorder. Psychopharmacology (Berl) 2004; 171: 405-412.
98. Alkhalil C, Tanvir F, Alkhalil B, Lowenthal DT. Treatment of sexual disinhibition in dementia: case reports and review of the literature. Am J Ther 2004; 11: 231-235.
99. McManaman J, Tam DA. Gabapentin for self-injurious behavior in Lesch-Nyhan syndrome. Pediatr Neurol 1999; 20: 381-382.
100. Gupta S, Frank BL, Masand PS. Gabapentin in the Treatment of Aggression Associated With Conduct Disorder. Prim Care Companion J Clin Psychiatry 2000; 2: 60-61.
101. Ryback R, Ryback L. Gabapentin for behavioral dyscontrol. Am J Psychiatry 1995; 152: 1399.
102. Barratt ES. The use of anticonvulsants in aggression and violence. Psychopharmacol Bull 1993; 29: 75-81.
103. Stanford MS, Helfritz LE, Conklin SM, et al. A comparison of anticonvulsants in the treatment of impulsive aggression. Exp Clin Psychopharmacol 2005; 13: 72-77.
104. Stanford MS, Houston RJ, Mathias CW, et al. A double-blind placebo-controlled crossover study of phenytoin in individuals with impulsive aggression. Psychiatry Res 2001; 103: 193-203.
105. Maletzky BM. The episodic dyscontrol syndrome. Dis Nerv Syst 1973; 34: 178-185.
106. Maletzky BM, Klotter J. Episodic dyscontrol: a controlled replication. Dis Nerv Syst 1974; 35: 175-179.
107. Barratt ES, Kent TA, Bryant SG, Felthous AR. A controlled trial of phenytoin in impulsive aggression. J Clin Psychopharmacol 1991; 11: 388-389.
108. Barratt ES, Stanford MS, Felthous AR, Kent TA. The effects of phenytoin on impulsive and premeditated aggression: a controlled study. J Clin Psychopharmacol 1997; 17: 341-349.
109. Keele NB. The role of serotonin in impulsive and aggressive behaviors associated with epilepsy-like neuronal hyperexcitability in the amygdala. Epilepsy Behav 2005; 7: 325-335.
110. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders IV-TR. Washington, DC: APA; 2000.
111. Nickel M, Nickel C, Leiberich P, et al. [Psychosocial characteristics in persons who often change their psychotherapists]. Wien Med Wochenschr 2004; 154: 163-169.
112. Skodol AE, Gunderson JG, Pfohl B, et al. The borderline diagnosis I: psychopathology, comorbidity, and personality structure. Biol Psychiatry 2002; 51: 936-950.
113. Skodol AE, Siever LJ, Livesley WJ, et al. The borderline diagnosis II: biology, genetics, and clinical course. Biol Psychiatry 2002; 51: 951-963.
114. Stone MH. The role of pharmacotherapy in the treatment of patients with borderline personality disorder. Psychopharmacol Bull 1989; 25: 564-571.
115. Swartz M, Blazer D, George L, Winfield I. Estimating the prevalence of borderline personality disorder in the community. J Personal Disord 1990; 4: 257-272.
116. Maier W, Lichtermann D, Klinger T, Heun R, Hallmayer JF. Prevalences of personality disorders (DSM-III-R) in the community. J Personal Disord 1992; 6: 187-196.
117. Hollander E. Managing aggressive behavior in patients with obsessive-compulsive disorder and borderline personality disorder. J Clin Psychiatry 1999; 60 Suppl 15: 38-44.
118. Skodol AE, Bender DS. Why are women diagnosed borderline more than men? Psychiatr Q 2003; 74: 349-360.
119. Kass F, Skodol AE, Charles E, Spitzer RL, Williams JB. Scaled ratings of DSM-III personality disorders. Am J Psychiatry 1985; 142: 627-630.
120. Piersma HL. The MCMI as a measure of DSM-III Axis II diagnoses: an empirical comparison. J Clin Psychol 1987; 43: 478-483.
121. Gunderson JG. Pharmacotherapy for patients with borderline personality disorder. Arch Gen Psychiatry 1986; 43: 698-700.
122. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988; 45: 111-119.
123. Gitlin MJ. Pharmacotherapy of personality disorders: conceptual framework and clinical strategies. J Clin Psychopharmacol 1993; 13: 343-353.
124. Coryell W. Rapid cycling bipolar disorder: clinical characteristics and treatment options. CNS Drugs 2005; 19: 557-569.
125. Davis LL, Ryan W, Adinoff B, Petty F. Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol 2000; 20: 1S-17S.
126. Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 1998; 59: 676-680.
127. Stein DJ, Simeon D, Frenkel M, Islam MN, Hollander E. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995; 56: 506-510.
128. Berlin HA, Rolls ET. Time perception, impulsivity, emotionality, and personality in self-harming borderline personality disorder patients. J Personal Disord 2004; 18: 358-378.
129. Berlin HA, Rolls ET, Kischka U. Impulsivity, time perception, emotion and reinforcement sensitivity in patients with orbitofrontal cortex lesions. Brain 2004; 127: 1108-1126.
130. Gardner DL, Cowdry RW. Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. Am J Psychiatry 1986; 143: 519-522.
131. Gardner DL, Cowdry RW. Development of melancholia during carbamazepine treatment in borderline personality disorder. J Clin Psychopharmacol 1986; 6: 236-239.
132. de la Fuente JM, Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 1994; 4: 479-486.
133. Bellino S, Paradiso E, Bogetto F. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 2005; 66: 1111-1115.
134. Nickel MK, Nickel C, Mitterlehner FO, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry 2004; 65: 1515-1519.
135. Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 2005; 57: 495-499.
136. Nickel MK, Loew TH. Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up. Eur Psychiatry 2008; 23: 115-117.
137. Loew TH, Nickel MK, Muehlbacher M, et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2006; 26: 61-66.
138. Killaspy H. Topiramate improves psychopathological symptoms and quality of life in women with borderline personality disorder. Evid Based Ment Health 2006; 9: 74.
139. do Prado-Lima PA, Kristensen CH, Bacaltchuck J. Can childhood trauma predict response to topiramate in borderline personality disorder? J Clin Pharm Ther 2006; 31: 193-196.
140. Preston GA, Marchant BK, Reimherr FW, Strong RE, Hedges DW. Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. J Affect Disord 2004; 79: 297-303.
141. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998; 51: 333-343.
142. Weinstein W, Jamison KL. Retrospective case review of lamotrigine use for affective instability of borderline personality disorder. CNS Spectr 2007; 12: 207-210.
143. Rizvi ST. Lamotrigine and borderline personality disorder. J Child Adolesc Psychopharmacol 2002; 12: 365-366.
144. Pavlovic ZM. Lamotrigine for the treatment of impulsive aggression and affective symptoms in a patient with borderline personality disorder comorbid with body dysmorphic disorder. J Neuropsychiatry Clin Neurosci 2008; 20: 121-122.
145. Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005; 19: 287-291.
146. Leiberich PK, Nickel MK, Tritt K, Gil FP. Lamotrigine treatment of aggression in female borderline patients, Part II: an 18-month follow-up. J Psychopharmacol 2008.
147. Stein G. Drug treatment of the personality disorders. Br J Psychiatry 1992; 161: 167-184.
148. Hori A. Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci 1998; 52: 13-19.
149. Coccaro EF, Kavoussi RJ. Biological and pharmacological aspects of borderline personality disorder. Hosp Commun Psychiatry 1991; 42: 1029-1033.
150. Pelissolo A, Lepine JP. [Pharmacotherapy in personality disorders: methodological issues and results]. Encephale 1999; 25: 496-507.
151. Biancosino B, Facchi A, Marmai L, Grassi L. Gabapentin treatment of impulsive-aggressive behaviour. Can J Psychiatry 2002; 47: 483-484.
152. Morana HC, Olivi ML, Daltio CS. [Use of gabapentin in group B - DSM-IV personality disorders]. Rev Bras Psiquiatr 2004; 26: 136-137.
153. Peris L, Szerman N, Ruiz M. [Efficacy and safety of gabapentin in Borderline Personality Disorder: a six-month, open-label study]. Vertex 2007; 18: 418-422.
154. Morana HC, Camara FP. International guidelines for the management of personality disorders. Curr Opin Psychiatry 2006; 19: 539-543.
155. Herranz JL. [Gabapentin: its mechanisms of action in the year 2003]. Rev Neurol 2003; 36: 1159-1165.
156. Slutske WS, Eisen S, Xian H, et al. A twin study of the association between pathological gambling and antisocial personality disorder. J Abnorm Psychol 2001; 110: 297-308.
157. Potenza MN, Steinberg MA, Skudlarski P, et al. Gambling urges in pathological gambling: a functional magnetic resonance imaging study. Arch Gen Psychiatry 2003; 60: 828-836.
158. Potenza MN, Leung HC, Blumberg HP, et al. An FMRI Stroop task study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry 2003; 160: 1990-1994.
159. Bechara A, Damasio H, Damasio AR, Lee GP. Different contributions of the human amygdala and ventromedial prefrontal cortex to decision-making. J Neurosci 1999; 19: 5473-5481.
160. O'Doherty J, Kringelbach ML, Rolls ET, Hornak J, Andrews C. Abstract reward and punishment representations in the human orbitofrontal cortex. Nat Neurosci 2001; 4: 95-102.
161. Hollander E, Pallanti S, Baldini Rossi N, et al. Imaging monetary reward in pathological gamblers. World J Biol Psychiatry 2005; 6: 113-120.
162. Hollander E, Buchalter AJ, DeCaria CM. Pathological gambling. Psychiatr Clin North Am 2000; 23: 629-642.
163. Hollander E, Frenkel M, Decaria C, Trungold S, Stein DJ. Treatment of pathological gambling with clomipramine. Am J Psychiatry 1992; 149: 710-711.
164. Hollander E, DeCaria CM, Mari E, et al. Short-term single-blind fluvoxamine treatment of pathological gambling. Am J Psychiatry 1998; 155: 1781-1783.
165. Hollander E, DeCaria CM, Finkell JN, et al. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry 2000; 47: 813-817.
166. Dannon PN, Lowengrub K, Gonopolski Y, Musin E, Kotler M. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 2005; 28: 6-10.
167. Kim SW. Opioid antagonists in the treatment of impulse-control disorders. J Clin Psychiatry 1998; 59: 159-164.
168. Moskowitz JA. Lithium and lady luck; use of lithium carbonate in compulsive gambling. N Y State J Med 1980; 80: 785-788.
169. Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry 2002; 63: 559-564.
170. Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry 2005; 162: 137-145.
171. Haller R, Hinterhuber H. Treatment of pathological gambling with carbamazepine. Pharmacopsychiatry 1994; 27: 129.
172. Nicolato R, Romano-Silva MA, Correa H, Salgado JV, Teixeira AL. Lithium and topiramate association in the treatment of comorbid pathological gambling and bipolar disorder. Aust N Z J Psychiatry 2007; 41: 628.
173. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361: 1677-1685.
174. Volkow ND, Fowler JS. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb Cortex 2000; 10: 318-325.
175. Dannon PN, Lowengrub K, Musin E, Gonopolsky Y, Kotler M. 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study. J Clin Psychopharmacol 2007; 27: 620-624.
176. Hollander E, Braun A, Chaplin W, Berlin HA, al. e. Double-blind, placebo-controlled trial of topiramate for pathological gambling. in preparation.
177. Dannon PN. Topiramate for the treatment of kleptomania: a case series and review of the literature. Clin Neuropharmacol 2003; 26: 1-4.
178. Shapira NA, Lessig MC, Murphy TK, Driscoll DJ, Goodman WK. Topiramate attenuates self-injurious behaviour in Prader-Willi Syndrome. Int J Neuropsychopharmacol 2002; 5: 141-145.
179. Shapira NA, Lessig MC, Lewis MH, Goodman WK, Driscoll DJ. Effects of topiramate in adults with Prader-Willi syndrome. Am J Ment Retard 2004; 109: 301-309.
180. Lochner C, Seedat S, Niehaus DJ, Stein DJ. Topiramate in the treatment of trichotillomania: an open-label pilot study. Int Clin Psychopharmacol 2006; 21: 255-259.
181. de Dios Perrino C, Santo-Domingo Carrasco J, Lozano Suarez M. [Pharmacological treatment of the intermittent explosive disorder. Report of three cases and literature review]. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1995; 23: 74-77.
182. Denicoff KD, Meglathery SB, Post RM, Tandeciarz SI. Efficacy of carbamazepine compared with other agents: a clinical practice survey. J Clin Psychiatry 1994; 55: 70-76.
183. Adu L, Lessig MC, Shapira NA. Topiramate in the treatment of trichotillomania. Southern Association for Research in Psychiatry 14th Annual Meeting, Gainesville, Florida 2001
184. Marazziti D, Dell'Osso B. Topiramate plus citalopram in the treatment of Compulsive-Impulsive Sexual Behaviors. Clin Pract Epidemol Ment Health 2006; 2: 9.
185. Kaufman KR, Kugler SL, Sachdeo RC. Tiagabine in the Management of Postencephalitic Epilepsy and Impulse Control Disorder. Epilepsy Behav 2002; 3: 190-194.
186. Grant JE, Odlaug BL, Kim SW. Lamotrigine treatment of pathologic skin picking: an open-label study. J Clin Psychiatry 2007; 68: 1384-1391.
187. Schupak C. Case report: lamotrigine/fluoxetine combination in the treatment of compulsive sexual behavior. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1337-1338.
188. Swann AC. Neuroreceptor mechanisms of aggression and its treatment. J Clin Psychiatry 2003; 64 Suppl 4: 26-35.
189. Coccaro EF. Impulsive aggression: a behavior in search of clinical definition. Harv Rev Psychiatry 1998; 5: 336-339.
190. Hollander E, Begaz T, DeCaria C. Pharmacological approaches in the treatment of pathological gambling. CNS Spectr 1998; 3: 72-80.
191. Hollander E, Sood E, Pallanti S, Baldini-Rossi N, Baker B. Pharmacological treatments of pathological gambling. J Gambl Stud 2005; 21: 99-110.